Citius Oncology, Inc. (CTOR)vsViatris Inc (VTRS)
CTOR
Citius Oncology, Inc.
$0.52
-5.46%
HEALTHCARE · Cap: $58.59M
VTRS
Viatris Inc
$20.67
-1.85%
HEALTHCARE · Cap: $23.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 207169% more annual revenue ($14.73B vs $7.11M). CTOR leads profitability with a 0.0% profit margin vs -4.1%. VTRS earns a higher WallStSmart Score of 40/100 (D).
CTOR
Avoid24
out of 100
Grade: F
VTRS
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CTOR.
Margin of Safety
-81.4%
Fair Value
$8.89
Current Price
$20.67
$11.78 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
ROE of -2.9% — below average capital efficiency
Revenue declined 0.3%
Earnings declined 70.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : CTOR
The strongest argument for CTOR centers on Price/Book, Debt/Equity.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book.
Bear Case : CTOR
The primary concerns for CTOR are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VTRS
The primary concerns for VTRS are PEG Ratio, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
CTOR profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
CTOR carries more volatility with a beta of 3.40 — expect wider price swings.
CTOR is growing revenue faster at 0.0% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (40/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Citius Oncology, Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Citius Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies tailored for underserved patient populations. With a robust pipeline of proprietary technologies, Citius aims to enhance treatment efficacy and safety across various cancer indications. The company is strategically advancing its promising drug candidates through pivotal clinical trials and regulatory processes, leveraging partnerships and rigorous clinical research standards to optimize patient outcomes and address critical needs in the oncology sector.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?